Monica Jefford
Research Subjects
Monica Jefford has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Anna M. Kirby
Royal Marsden NHS Foundation Trust, Sutton, UK
2 shared publications - Charlotte E. Coles
Department of Oncology, University of Cambridge, Cambridge, CB2 0QQ, UK
2 shared publications - Cliona Clare Kirwan
Institute of Cancer Sciences, University of Manchester, University Hospital of South Manchester, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, Oxford Road, Manchester M13 9PL, United Kingdom
2 shared publications - Indrani Subarna Bhattacharya
The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU), United Kingdom
2 shared publications - Joanne Haviland
Pragmatic Clinical Trials Unit, Centre for Evaluation and Methods, Faculty of Medicine and Dentistry, Wolfson Institute of Population Health Queen Mary University of London London UK
2 shared publications - Judith M. Bliss
Clinical Trials and Statistics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111301
Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials
- 27 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111301
Open AccessBaseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials
- Open Access
- 23 July 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 211, 111056
Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial
- 23 July 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 211, 111056
Open AccessFive-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial
- Open Access
- 17 September 2018
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 91 (1092) , 20180325
Recommendations for clinical translation of nanoparticle-enhanced radiotherapy
A multi-disciplinary cooperative for nanoparticle-enhanced radiotherapy (NERT) has been formed to review the current status of the field and identify key stages towards translation. Supported by the Colorectal Cancer Healthcare Technologies Cooperative, the cooperative comprises a diverse cohort of key contributors along the translation pathway including academics of physics, cancer and radio-biology, chemistry, nanotechnology and clinical trials, clinicians, manufacturers, industry, standards laboratories, policy makers and patients. Our aim was to leverage our combined expertise to devise solutions towards a roadmap for translation and commercialisation of NERT, in order to focus research in the direction of clinical implementation, and streamline the critical pathway from basic science to the clinic. A recent meeting of the group identified barriers to and strategies for accelerated clinical translation. This commentary reports the cooperative’s recommendations. Particular emphasis was given to more standardised and cohesive research methods, models and outputs, and reprioritised research drivers including patient quality of life following treatment. Nanoparticle design criteria were outlined to incorporate scalability of manufacture, understanding and optimisation of biological mechanisms of enhancement and in vivo fate of nanoparticles, as well as existing design criteria for physical and chemical enhancement. In addition, the group aims to establish a long-term and widespread international community to disseminate key findings and create a much-needed cohesive body of evidence necessary for commercial and clinical translation.
- 17 September 2018
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 91 (1092) , 20180325
Open AccessRecommendations for clinical translation of nanoparticle-enhanced radiotherapy
A multi-disciplinary cooperative for nanoparticle-enhanced radiotherapy (NERT) has been formed to review the current status of the field and identify key stages towards translation. Supported by the Colorectal Cancer Healthcare Technologies Cooperative, the cooperative comprises a diverse cohort of key contributors along the translation pathway including academics of physics, cancer and radio-biology, chemistry, nanotechnology and clinical trials, clinicians, manufacturers, industry, standards laboratories, policy makers and patients. Our aim was to leverage our combined expertise to devise solutions towards a roadmap for translation and commercialisation of NERT, in order to focus research in the direction of clinical implementation, and streamline the critical pathway from basic science to the clinic. A recent meeting of the group identified barriers to and strategies for accelerated clinical translation. This commentary reports the cooperative’s recommendations. Particular emphasis was given to more standardised and cohesive research methods, models and outputs, and reprioritised research drivers including patient quality of life following treatment. Nanoparticle design criteria were outlined to incorporate scalability of manufacture, understanding and optimisation of biological mechanisms of enhancement and in vivo fate of nanoparticles, as well as existing design criteria for physical and chemical enhancement. In addition, the group aims to establish a long-term and widespread international community to disseminate key findings and create a much-needed cohesive body of evidence necessary for commercial and clinical translation.
- Open Access
- 16 July 2018
- Published by Springer Nature in Research Involvement and Engagement
- Vol. 4 (1) , 1-7
Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies
Breast cancer is a diverse and varied disease. Recent research has shown that the collection of multiple biopsies before surgery can help researchers determine how the cancer is responding to treatment and can predict for long-term outcomes. However biopsies can be uncomfortable, and sometimes clinicians and research teams in hospitals may be reluctant to offer clinical trials requiring several biopsies to patients who have been recently diagnosed with breast cancer. The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) oversees a large number of breast cancer clinical trials where multiple biopsies are required. ICR-CTSU recognises that patient advocates (patients who have previously had, or cared for someone with, cancer) are key members of the trial design group and should be involved in the clinical trial throughout its lifespan. Patient advocates can provide reassurance regarding the acceptability of trial designs involving multiple biopsies from a patient perspective. This paper summarises patient advocate involvement in ICR-CTSU breast cancer trials activity and how this has benefited our research. The importance of collecting tissue samples in breast cancer has become increasingly recognised, as the diversity of the disease has become better known. It has been documented in recent research that tumours may change in response to treatment prior to surgery (the neoadjuvant treatment setting). The collection of sequential biopsies over time can identify changes within tumours and potentially predict how the tumour may respond to certain treatments. However, the acceptability of multiple biopsies amongst patients, clinicians and other research staff in hospitals is variable and recruitment into clinical trials requiring multiple biopsies may be challenging. The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) is responsible for a portfolio of breast cancer trials where multiple biopsies are key to the trial design. Patient advocate involvement has been essential in helping us to design and deliver complex and innovative cancer trials which require multiple invasive tissue biopsies, often without any direct benefit to the trial participants. The views expressed by patient advocates involved in ICR-CTSU trials supports the published evidence that patients are willing to donate additional tissue for research and that clinicians’ concerns about approaching patients for trials involving multiple biopsies are often unfounded. Patient advocate involvement in ICR-CTSU trials activity takes various forms, from membership on protocol development groups and trial management groups, attendance at focus groups and forums, and presentations at trial development and launch meetings. This involvement has provided reassurance to research teams within the NHS and research ethics committees of the importance and acceptability of our trials from a patient perspective. Patient advocate involvement throughout the lifetime of our trials ensures that the patient remains central to our research considerations.
- 16 July 2018
- Published by Springer Nature in Research Involvement and Engagement
- Vol. 4 (1) , 1-7
Open AccessPatient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies
Breast cancer is a diverse and varied disease. Recent research has shown that the collection of multiple biopsies before surgery can help researchers determine how the cancer is responding to treatment and can predict for long-term outcomes. However biopsies can be uncomfortable, and sometimes clinicians and research teams in hospitals may be reluctant to offer clinical trials requiring several biopsies to patients who have been recently diagnosed with breast cancer. The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) oversees a large number of breast cancer clinical trials where multiple biopsies are required. ICR-CTSU recognises that patient advocates (patients who have previously had, or cared for someone with, cancer) are key members of the trial design group and should be involved in the clinical trial throughout its lifespan. Patient advocates can provide reassurance regarding the acceptability of trial designs involving multiple biopsies from a patient perspective. This paper summarises patient advocate involvement in ICR-CTSU breast cancer trials activity and how this has benefited our research. The importance of collecting tissue samples in breast cancer has become increasingly recognised, as the diversity of the disease has become better known. It has been documented in recent research that tumours may change in response to treatment prior to surgery (the neoadjuvant treatment setting). The collection of sequential biopsies over time can identify changes within tumours and potentially predict how the tumour may respond to certain treatments. However, the acceptability of multiple biopsies amongst patients, clinicians and other research staff in hospitals is variable and recruitment into clinical trials requiring multiple biopsies may be challenging. The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) is responsible for a portfolio of breast cancer trials where multiple biopsies are key to the trial design. Patient advocate involvement has been essential in helping us to design and deliver complex and innovative cancer trials which require multiple invasive tissue biopsies, often without any direct benefit to the trial participants. The views expressed by patient advocates involved in ICR-CTSU trials supports the published evidence that patients are willing to donate additional tissue for research and that clinicians’ concerns about approaching patients for trials involving multiple biopsies are often unfounded. Patient advocate involvement in ICR-CTSU trials activity takes various forms, from membership on protocol development groups and trial management groups, attendance at focus groups and forums, and presentations at trial development and launch meetings. This involvement has provided reassurance to research teams within the NHS and research ethics committees of the importance and acceptability of our trials from a patient perspective. Patient advocate involvement throughout the lifetime of our trials ensures that the patient remains central to our research considerations.